Melanoma in the brain: biology and therapeutic options

被引:41
作者
Gibney, Geoffrey Thomas [1 ,3 ]
Forsyth, Peter A. [2 ,3 ]
Sondak, Vernon K. [1 ,3 ,4 ]
机构
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Neuro Oncol, Tampa, FL 33612 USA
[3] Univ S Florida, Coll Med, Dept Oncol Sci, Tampa, FL 33612 USA
[4] Univ S Florida, Coll Med, Dept Surg, Tampa, FL 33612 USA
关键词
biology; BRAF; brain metastasis; ipilimumab; melanoma; therapy; METASTATIC MELANOMA; CEREBRAL METASTASES; RADIATION-THERAPY; PHASE-II; STEREOTACTIC RADIOSURGERY; MALIGNANT-MELANOMA; SURGICAL RESECTION; TEMOZOLOMIDE; RADIOTHERAPY; IRRADIATION;
D O I
10.1097/CMR.0b013e328352dbef
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The development of brain metastases is a frequent occurrence in patients with disseminated melanoma and contributes to a disproportionate degree of morbidity and mortality. The prognosis is markedly reduced once a patient is diagnosed with central nervous system disease. Definitive therapeutic interventions with resection or stereotactic radiosurgery have improved outcomes and become standard approaches in the management of melanoma brain metastases. With the inclusion of whole-brain radiation in these interventions, there has been a reduction in local recurrences, but no improvement in the overall survival. Still, many patients are not candidates for surgery nor radiotherapy nor develop progressive central nervous system disease after definitive therapy. As new immune-based and targeted therapeutic agents are developed for the treatment of metastatic melanoma, understanding their activity in brain metastases is necessary for effective patient management. In this review, we discuss the biology of brain metastases in metastatic melanoma, current treatment approaches with surgery and radiotherapy, and future systemic therapeutic strategies. Melanoma Res 22: 177-183 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:177 / 183
页数:7
相关论文
共 63 条
[1]   Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study [J].
Agarwala, SS ;
Kirkwood, JM ;
Gore, M ;
Dreno, B ;
Thatcher, N ;
Czarnetski, B ;
Atkins, M ;
Buzaid, A ;
Skarlos, D ;
Rankin, EM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2101-2107
[2]   STEREOTAXIC RADIOSURGERY FOR THE DEFINITIVE, NONINVASIVE TREATMENT OF BRAIN METASTASES [J].
ALEXANDER, E ;
MORIARTY, TM ;
DAVIS, RB ;
WEN, PY ;
FINE, HA ;
BLACK, PM ;
KOOY, HM ;
LOEFFLER, JS .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (01) :34-40
[3]   Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial [J].
Andrews, DW ;
Scott, CB ;
Sperduto, PW ;
Flanders, AE ;
Gaspar, LE ;
Schell, MC ;
Werner-Wasik, M ;
Demas, W ;
Ryu, J ;
Bahary, JP ;
Souhami, L ;
Rotman, M ;
Mehta, MP ;
Curran, WJ .
LANCET, 2004, 363 (9422) :1665-1672
[4]  
[Anonymous], 2022, CLIN PRACTICE GUIDEL
[5]  
[Anonymous], J CLIN ONCOL S
[6]   Temozolomide, Thalidomide, and Whole Brain Radiation Therapy for Patients With Brain Metastasis From Metastatic Melanoma A Phase II Cytokine Working Group Study [J].
Atkins, Michael B. ;
Sosman, Jeffrey A. ;
Agarwala, Sanjiv ;
Logan, Theodore ;
Clark, Joseph I. ;
Ernstoff, Marc S. ;
Lawson, David ;
Dutcher, Janice P. ;
Weiss, Geoffrey ;
Curti, Brendan ;
Margolin, Kim A. .
CANCER, 2008, 113 (08) :2139-2145
[7]   Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study [J].
Avril, MF ;
Aamdal, S ;
Grob, JJ ;
Hauschild, A ;
Mohr, P ;
Bonerandi, JJ ;
Weichenthal, M ;
Neuber, K ;
Bieber, T ;
Gilde, K ;
Porta, VG ;
Fra, J ;
Bonneterre, J ;
Saïag, P ;
Kamanabrou, D ;
Pehamberger, H ;
Sufliarsky, J ;
Larriba, JLG ;
Scherrer, A ;
Menu, Y .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1118-1125
[8]   Survival by Radiation Therapy Oncology Group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma - A retrospective study [J].
Buchsbaum, JC ;
Suh, JH ;
Lee, SY ;
Chidel, MA ;
Greskovich, JF ;
Barnett, GH .
CANCER, 2002, 94 (08) :2265-2272
[9]   Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases [J].
Capper, David ;
Berghoff, Anna Sophie ;
Magerle, Manuel ;
Ilhan, Ayseguel ;
Woehrer, Adelheid ;
Hackl, Monika ;
Pichler, Josef ;
Pusch, Stefan ;
Meyer, Jochen ;
Habel, Antje ;
Petzelbauer, Peter ;
Birner, Peter ;
von Deimling, Andreas ;
Preusser, Matthias .
ACTA NEUROPATHOLOGICA, 2012, 123 (02) :223-233
[10]   Modelling of the blood-brain barrier in drug discovery and development [J].
Cecchelli, Romeo ;
Berezowski, Vincent ;
Lundquist, Stefan ;
Culot, Maxime ;
Renftel, Mila ;
Dehouck, Marie-Pierre ;
Fenart, Laurence .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (08) :650-661